Chuangybang learned that recently, Zhixiang Biologics (Suzhou) Co., Ltd. "English name: Intellective Biologics (Suzhou) Co., Ltd., hereinafter referred to as "Zhixiang Biologics", announced the completion of the C round of financing, with a financing amount of more than 500 million yuan. This round of financing was jointly led by Gaorong Capital and Qingsong Capital, followed by Fuhui Venture Capital, CNCBI Investment Beijing, Founder Securities Investment, Wenhua Haihui, etc., with Sanjiang Capital as the exclusive financial advisor.
As an old shareholder, Qingsong Capital has once again blessed it, which shows the in-depth cooperative relationship and long-term trust established by Zhixiang Bio and investors, and the joining of professional investment institutions in the biomedical field such as Gaorong Capital also reflects the continuous recognition and sustained growth of the capital market. This round of financing will be used for the rapid expansion of commercial production capacity, the comprehensive upgrading of the technology platform, the strategic layout of international operation and the expansion of talent teams.
Founded in April 2018, Zhixiang Bio focuses on the development of macromolecular biopharmaceutical processes and large-scale commercial production of CDMO, and the cutting-edge process development technology platform has achieved many achievements, and is one of the few CDMO enterprises with core technology, large-scale mass production and commercialization closed-loop comprehensive capabilities.
Zhixiang Bio has seven CDMO technology platforms, covering GMP production platform, ADC platform, multiple culture platforms, autonomous cell construction platforms, druggability analysis platforms, virus safety detection platforms, and preparation development platforms. The company has production bases in Suzhou Xiangcheng High-tech Zone, Industrial Park and Changshu High-tech Zone, and all bases have started flexible production line expansion projects, and the total planned production capacity will reach 220,000 liters in 2023, with the world's leading production capacity and cost advantages.
As a CDMO enterprise with a leading process development technology platform in the industry, Zhixiang Biological Service category covers monoclonal antibodies, double antibodies, multiple antibodies, fusion proteins, vaccines, ADCs, etc., and is also one of the few enterprises in China that can produce ADC drugs.
Zhixiang Bio adopts the platform-based monoclonal antibody production process to shorten the process development time, and it takes only 3 months from molecular determination to delivery of 200L samples in a trispecific antibody project; By using platformed production materials, material procurement time was reduced, and the biisotropic antibody project was transferred from cells to delivery samples in just 7 weeks. The ultimate project research and development cycle, flexible and innovative process development, fully empower new drug customers to seize market opportunities.
In addition to having obvious advantages in terms of execution speed, Zhixiang Bio is gradually growing into a powerful and reliable biopharmaceutical manufacturer. The company strengthens the quality system internally, continuously optimizes and upgrades the process, and provides stable guarantee for cooperative enterprises. In addition, the company strengthens strategic cooperation with local enterprises to achieve a high level of control over commercial production costs through a supply chain system that combines cooperative development and independent research and development.
In turn, it effectively helps customers reduce the total cost of research and development, integrate various resources with high quality, and provide customers with more competitive and comprehensive solutions in the fierce market competition and challenging payment environment. In the future, Zhixiang Bio will continue to deepen the subdivision track, continuously improve the volume and overall production capacity of the enterprise, further deepen the moat of the enterprise with differentiated services, and enhance the international competitiveness of the enterprise.
At present, the global biopharmaceuticals are in a period of rapid development, and their market size is growing year by year, and will exceed $500 billion by 2025. Worldwide investment in drug R&D is also increasing year by year, with global R&D spending expected to reach $204 billion by 2024. In recent years, the number of new drugs approved by the FDA has also increased. Under the encouragement of the international situation and domestic policies, the number of declarations and IND approvals of bio-innovative drugs in mainland China is also increasing, promoting more bio-drugs to enter the commercialization stage.
In the global Top100 drug sales, biological drugs account for more than small molecule drugs, and the clinical phase III project will bring a new round of opportunities to the CDMO industry. Industry data show that the global biopharmaceutical CDMO market has an average annual compound growth rate of more than 20%, and the mainland macromolecular drug CDMO market has maintained a growth rate of 40%. The CDMO industry is in a golden age of development, while the biomedical CDMO industry will have a blowout and rise rapidly in the next few years.
Li Zhi, CEO of Zhixiang Biotech, said: "We are committed to promoting more new drugs to accelerate the listing, and have accumulated rich experience in the process of practice to find the optimal solution path for the whole process of IND to BLA services. Zhixiang Bio is in a leading position in technology, and under the layout of the whole industry chain, it has rapidly realized large-scale production and has been widely recognized by the industry, contributing to China's biological 'intelligent' manufacturing.
We will also maintain the vision and values of long-term development, help customers in decision-making difficulties, prepare for long-term development, and adhere to the path of sustainable business. Thanks to the trust of investors and the support of our customers, we will continue to focus on the CDMO field and explore the infinite possibilities. Let Zhixiang Bio become a leading enterprise in the field of CDMO in the world, with a view to benefiting more patients. ”
Li Jing, head of qingsong capital project, said: With the emergence of major breakthroughs in the technical end and clinical application field of macromolecular drugs in recent years, the development of the industry has entered a new important stage, and the professional one-stop CDMO platform will play an important nodal value in this process. The Zhixiang Bio team has rich experience in the development and industrialization of macromolecular drug processes, and has not only cooperated closely for a long time, but also has strong execution.
Qingsong Capital has been focusing on the investment of the whole industry chain of life and health, and continues to pay attention to and support the development and innovation of the supply chain with strategic partners. It is expected that the company will further improve its efficiency and cost advantages with the support of this round of financing, build an industry-leading technology platform and service quality system, provide customers with more high-quality whole-industry chain solutions, empower the global new drug industry research and development and commercialization process, and bring more efficient and accessible advanced therapies to patients.
Le Bellin, Executive Director of Gaorong Capital, said: "As more biological drugs around the world continue to advance from early research and development to commercial production, the platform technology has also been expanded horizontally from monoclonal antibodies to multiple antibodies, fusion proteins, ADCs, etc., which is both a huge opportunity for CDMO companies and a new challenge.
As a one-stop CDMO service platform, Zhixiang Bio provides customers with fast and stable solutions through the ultimate R&D cycle and mature supply chain system, the so-called fast as the wind, its Xu Rulin. Behind it is the experienced team of Zhixiang Bio, a strong technical platform, and a large-scale and systematic supply chain as support. We are also optimistic about the further expansion of production capacity and internationalization route in the next step, empowering more customers around the world to develop new drugs. ”
This article originated from Chuangyebang
![This social e-commerce company was recovered! Sequoia IDG Hillhouse and other investments[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)